Send us a text🧠 Clinical Problem:HFpEF (Heart Failure with Preserved EF) has lacked effective, proven therapies.Finerenone (non-steroidal MRA) offers new hope.🧪 FINEARTS-HF Trial:6,000+ patients with EF ≥40%, followed for ~32 months.Compared Finerenone vs placebo.📈 Results:↓ Heart failure hospitalization significantly.No significant reduction in CV mortality.Hyperkalemia: 9.7% (Finerenone) vs 4.2% (Placebo).🧩 Clinical Takeaway:May offer benefit for HFpEF — especially if SGLT2i also used.Expensive; Spironolactone may be a lower-cost alternative with similar benefit.Important addition to the limited HFpEF toolbox.

Ver todos los episodios